Compound42
Oncology (solid tumors)
Pre-clinicalActive
Key Facts
About Abbmira Therapeutics
Abbmira Therapeutics is an early-stage, private biotechnology company pioneering a novel approach to cancer immunotherapy by reprogramming the native immune system, specifically tumor-associated macrophages. The company's core technology is a small-molecule drug, Compound42, which targets a specific immune pathway to switch macrophages from a pro-tumor to an anti-tumor state. Operating from Basel, Switzerland, Abbmira is positioned in the competitive oncology space with a promising pre-clinical asset that could address limitations of current therapies. The company is actively seeking partnerships and investment to advance its lead program toward clinical development.
View full company profileTherapeutic Areas
Other Oncology (solid tumors) Drugs
| Drug | Company | Phase |
|---|---|---|
| OATD-02 | Molecure | Phase I |
| ANXV | Annexin Pharmaceuticals | Preclinical |
| Athebody® DARPins for Targeted Radioligands (with POINT Biopharma) | Athebio | Pre-clinical |
| AB821 | Asher Biotherapeutics | Preclinical |
| VEGF Kinoid | Neovacs | Preclinical |
| Undisclosed Preclinical Pipeline | OncoResponse | Preclinical |
| Undisclosed Platform Program | Da Zen Theranostics | Pre-clinical |
| Clinical Decision Support Service | Curematch | Commercial |
| CV6-168 | CV6 Therapeutics | Phase 1a |
| Chemophototherapy (CPT) | POP Biotechnologies | Pre-clinical |
| HRD Testing Solution | SeqOne Genomics | Commercial |
| Platform Validation & Partnership Development | SingleCell Biotechnology | Pre-clinical |